In this piece, we will take a look at the 13 best momentum stocks to buy now. If you want to skip our overview of the different kinds of trading strategies and some latest stock market news, then you can take a look at the 5 Best Momentum Stocks To Buy Now. When it comes […]
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
Insightful Analysis of Eli Lilly's Market Position and Future Prospects